Member Info for Moneymunch

A compelling, insightful and exciting podcast on Sirt6's strong and promising potential and influence in longevity and multiple disease targets, with study results expected soon. Gla :-)

Podcast interview with Vera Gorbunova from 24/10/2÷ discussing the promising potential for Sirt6 and how she is conducting research in collaboration with Biotech companies, and confirms results should be available in a few months. Gla :-)

SIRT6 The Science Behind The Longevity Gene | Professor Vera Gorbunova Ep1

Oct. 24, 2023

htTps://www.listennotes.com/podcasts/modern-healthspan/sirt6-the-science-behind-the-Z8u9qApmey_/

GenFlow Biosciences partnership with Revatis SA and EXO Biologics in Groundbreaking Aging Research, Fueled by Two Major Research Grants 🧬

View organization page for Revatis

Revatis

659 followers

1mo

An excellent start to 2024: our intellectual property is strengthened by the granting of a patent in South Korea, very useful for our tissue engineering projects. #tissueengineering #stemcells #regenerativemedicine #celltherapy #cellandgenetherapy

Updates

View organization page for Revatis

Revatis

659 followers

16h

In Australia, too, our intellectual property rights have been strengthened by the granting of this new patent covering new uses for our technology.

hTtps://www.linkedin.com/company/revatis

EXO Biologics

2,052 followers

3d

📢 Press Release: ExoXpert Launched by EXO Biologics to Meet Global Exosome Demand.

We are thrilled to announce the worldwide launch of ExoXpert, a cutting-edge contract development and manufacturing organization (CDMO) by EXO Biologics . ExoXpert, with the ExoPulse, platform is dedicated to addressing the increasing demand for exosomes in the biopharmaceutical industry.

"Our vision for ExoXpert is to provide specialized exosome manufacturing capabilities to meet the increasing needs of the market," stated Romain du Hecquet de Rauville, Chief Business Officer at EXO Biologics. "With the launch of ExoXpert, we aim to make a significant contribution to the advancement of exosome-based therapies."

🌐 ExoXpert's Key Features:

🚀 The ExoPulseTM manufacturing platform, designed by EXO Biologics and used in clinical trial, to provide clients a fast-track access to clinic.

🚀 R&D exosome vials on demand

🚀 State-of-the-art exosome manufacturing plant with Grade A/B and C clean rooms.

🚀 Specialized staff and management committed to quality and innovation.

"I'm proud to witness ExoXpert's launch," said Hugues Wallemacq, CEO of EXO Biologics. "This initiative not only tackles the hurdles in exosome production and characterization but also propels the advancement of exosome-based therapeutics on a global scale."

hTps://be.linkedin.com/company/exo-biologics

Link to Full Press Release: htTps://lnkd.in/d-btKWJR

· Develop and implement project management, budgeting and governance for collaborative partners, in line with clinical and pre-clinal activities that will enable IND applications.

· Moving key patent applications under the Patent Cooperation Treaty (PCT) to the national phase, while further expanding our development pipeline with new products and new indications.

Dr. Eric Leire, CEO of Genflow commented: "The milestones we reached in 2023 were numerous, and I commend our team for their exceptional commitment to execution and delivery. While 2023 was a pivotal year, we're poised for an even stronger 2024, as we shift focus to scaling development of our lead drug candidate, GF-1002, and its potential benefits for NASH patients. With the support of our partners and the backing of new grants, we are poised to make meaningful advancements in the field of longevity."

RNS Number : 4088B

Genflow Biosciences PLC

01 February 2024

1 February 2024

Genflow Biosciences Plc

("Genflow" or "the Company")

Genflow Biosciences Releases 2023 Year-End Review and Highlights Key Priorities for 2024

The Company (LSE:GNF) (OTCQB:GENFF), an emerging leader in the field of longevity research developing therapeutics that potentially halt or slow the ageing process, is pleased to provide a year-end review and summary of its progress during 2023 and defined strategic priorities for 2024.

The Company achieved many significant accomplishments throughout the year across all aspects of its business. The full year-end review can be viewed on Genflow's website: https://genflowbio.com/genflow-biosciences-plc-2023-year-in-review/.

Key 2023 Highlights:

· Genflow expanded its intellectual property portfolio with a provisional patent application for editing the SIRT6 gene, linked to longevity and age-related diseases.

· Began trading on the OTCQB Venture Market in the US under the ticker GENFF, aligned to its US-focused strategy.

· Genflow received positive feedback from the Federal Agency for Medicines and Health Products in Belgium on the design of Phase I/II clinical trials for its lead drug candidate, GF-1002, in NASH patients.

· Genflow made several key appointments, including Capital Plus Partners Ltd as Joint Broker in order to access both institutional and international investment; Harbor Access for investor relations support; and Prof. Dr. Sven Francque, an expert in nonalcoholic fatty liver disease and Prof. Dr. Mary E. Rinella, a fatty liver disease specialist to its Scientific Advisory Board.

Strategic Priorities in 2024:

· Genflow awarded 2.89 million Euros in two new grants that will broaden its research pipeline and expand the size of its therapeutic markets over the next three years. (Refer to press release: https://www.globenewswire.com/news-release/2024/01/18/2811445/0/en/Genflow-Biosciences-Partners-with-Revatis-SA-and-EXO-Biologics-in-Groundbreaking-Aging-Research-Fueled-by-Two-Major-Research-Grants.html)

· Genflow to undertake key Investigational New Drug (IND)-enabling development activities that will help define the pharmacological and toxicological properties of its lead drug candidate, GF-1002, and its potential benefits for NASH patients.

· Initial site selection and QMS framework for clinical readiness, expected by the end of 2025 for the NASH program.

· Commence preliminary discussions with the European Medicines Agency (EMA) on Mechanism of Action (MoA) data for Orphan Drug Application (ODA) for our second compound GF-3001, targeting Werner Syndrome.

· Select Contract Development and Manufacturing Organization (CDMO) for advancing the GMP manufacturing of the NASH clinical lot of lead drug candidate, GF-1002.

· Develop and implement pr

Too many punters have sold their shares too cheaply, me thinks...Gla holders...On and UP!!! :-)

Genflow Biosciences PLC (LSE:GENF, OTCQB:GENFF) chief executive officer Dr. Eric Leire spoke with Proactive's Stephen Gunnion to discuss the impact of two substantial research grants awarded to Genflow in Belgium.

These grants are not just financial boons but are fostering critical collaborations in the field of advanced therapy medicinal products (ATMPs), marking a new era in biotechnological research and development.

Stephen Gunnion (SG): Dr. Leire, can you elaborate on the scope of these grants and their importance for Genflow Biosciences?

Eric Leire (EL): These grants are a major milestone for us. They primarily focus on enhancing collaborations in advanced therapy medicinal products, or ATMPs. Specifically, they support our partnerships with EXO Biologics for exosome manufacturing and Revatis SA for sarcopenia research. Sarcopenia, the age-related muscle loss condition, is a critical research area for Genflow. The grants cover 80% of the project costs, which is substantial financial backing, allowing us to enhance our research capabilities significantly.

SG: Could you shed some light on how these collaborations align with Genflow’s broader strategic goals?

EL: Absolutely. These collaborations are integral to our three-year plan of building a robust biotech ecosystem in Belgium. By working closely with academic centres and various biotech actors, we aim to significantly bolster our research capabilities. This not only enhances our company valuation through meaningful milestones but also strengthens our position in the biotech market by increasing shareholder value and validating the scientific rigour of our research.

SG: With such a focused approach towards ATMPs and age-related diseases, what are the long-term implications for Genflow's research portfolio?

EL: Our long-term vision is to expand our pipeline, focusing on gene therapy and age-related diseases. This strategy is designed to mitigate financial and scientific risks in the challenging biotech market. By diversifying and strengthening our research portfolio, we aim to establish Genflow as a leader in biotech innovation, particularly in the field of longevity and age-related conditions.

SG: Finally, what are the future plans for Genflow in terms of collaborations and research directions?

EL: Looking ahead, we are actively seeking further collaborations to expand our pipeline. While we remain dedicated to gene therapy and tackling age-related diseases, our goal is to create a diversified research portfolio that can withstand market challenges. This approach is essential for sustainable growth and continued innovation in biotechnology.

Appointed Prof. Dr. Mary E. Rinella, Director, Metabolic and Fatty Liver Disease Department at the University of Chicago. She has investigated a broad range of topics within fatty liver disease, including the use of non-invasive measures to minimize the use of liver biopsy and the study of new therapies to treat fatty liver disease, since there is still no FDA approved treatment. Dr. Rinella has published nearly 150 peer-review articles in prestigious journals, such as Nature Reviews Gastroenterology & Hepatology, Gastroenterology, Hepatology, Journal of the American Medical Association (JAMA), The Lancet and others.

Heading into 2024, Genflow is well placed to take advantage of the recent resurgence of interest in the longevity sector. We continue to monitor opportunities, and to prioritize marketing efforts to expand our investor audience in North America and Europe. Our commitment to innovation and improving lives remains steadfast, as we navigate the opportunities and challenges that lie ahead. Together, we envision a future where our pioneering work redefines possibilities, bringing hope and transformative solutions to those who need it most.

Dr. Eric Leire

Founder and CEO

Genflow Biosciences Plc

January 25, 2024

Key Milestones

Q1 2023: Issued a shareholder update on the Company’s progress, highlighting our expanded intellectual property portfolio through a provisional patent application focusing on the ability to edit the SIRT6 gene, shown to play a role in longevity and age-related diseases as well as our solid cash position.

Q2 2023: Expanded our intellectual property portfolio through a provisional patent application focusing on the ability to edit the SIRT6 gene, shown to play a role in longevity and age-related diseases. If successful, the patent will represent a significant breakthrough in the field of gene editing, with potential implications for longevity and other forms of gene therapy;

Genflow started trading on the OTCQB Venture Market in the US under the ticker GENFF. This move aligns with our strategic emphasis on the US due to its significant advancements in longevity and our ongoing collaborations with US-based institutions;

The Company appointed Prof. Dr. Sven Francque on our Scientific Advisory Board. Prof. Francque is currently Chairman of the Department of Gastroenterology and Hepatology of the University Hospital Antwerp and Full Professor of Medicine at the Faculty of Medicine and Health Sciences of the University of Antwerp in Belgium. He has a longstanding interest and expertise in nonalcoholic fatty liver disease and conducted [basic] research focusing on steatosis. His research unit continues to study pathophysiological mechanisms of NASH. He also conducts clinical research, and his unit is a partner in several research consortia supported by the European Commission.

Q3 2023: Received positive comments from the Federal Agency for Medicines and Health Products (FAHMP) of Belgium regarding the design of our upcoming Phase I/II clinical trials of our lead drug candidate, GF-1002 with patients suffering from NASH. Following our encouraging results from in-vitro human cell and in-vivo rodent studies, the Agency concurred with Genflow’s proposal to commence clinical trials directly with NASH patients, thereby bypassing Phase I trials with healthy volunteers;

Appointed Harbor Access, a strategic Investor Relations firm with offices in the US and Canada to provide investor relations support and investor outreach.

Q4 2023: Appointed Capital Plus Partners Ltd (“CPP”) to act as Joint Broker, alongside Clear Capital Markets Limited. The addition of CPP is expected to bring additional expertise to the Company, strengthen our position and improve access to the capital;

Genflow Biosciences Plc 2023 Year in Review

2023 was a busy and productive year for Genflow Biosciences Plc (“Genflow) marked by significant advancements in our mission to pioneer novel therapeutics for a longer, healthier life. The groundbreaking gene therapies that we are working on alongside our co-collaborators are being engineered to target both the ageing process, and reduce and delay the onset of age-related diseases. Our mission remains to lower healthcare expenditures while easing the emotional and social challenges associated with an ageing population.

We’ve made numerous strategic moves this year as a part of our ongoing efforts to strengthen our company, financial and market position. Our balance sheet remains strong, and we are in a solid financial position. To comply with the updated requirements of the existing grant from the Wallonia region, and to be eligible for future grant funding, we undertook an internal debt re-organization without dilution. This puts us in a favorable financial position compared to many other biotechnology companies.

We diligently continue to pursue the research, development, and safe implementation of our two pivotal programs centered on NASH (Non-Alcoholic Steatohepatitis) and Werner Syndrome and have made significant progress this year.

NASH. We are pleased to report that our NASH program, which afflicts an estimated 35 million individuals worldwide and ranks among the leading causes of chronic liver disease with the urgent need for life-saving liver transplants, is progressing to plan. This program is advancing steadily, underscoring our firm commitment to combatting this pressing global health issue. In collaboration with Dr. Manlio Vinciguerra, (a Genflow Scientific Advisory Board member based at the University of Liverpool), are gaining a significantly deeper understanding of the biochemical changes that occur in the treatment of NASH using the centenarian SIRT6. This research has led to us clearly identifying the workings of our lead drug candidate, GF-1002 and its potential benefits for NASH patients. As a result, we have accumulated important data and filed a new patent application on this specific activity. Additionally, NASH clinical trials are expected to begin in Q1-Q2 2025 following dialogue and subsequent agreement with the European Medicine Agency.

Werner Syndrome.

Simultaneously, we are making progress targeting Werner Syndrome, an accelerated ageing disease. Here, our vision is clear: to enhance the quality of life for affected patients and expedite the path towards swift and successful first-in-human trials under orphan drug designation. Our lead compound GF-3001, is a topical delivery of SIRT6 to the skin.

Updates

View organization page for Genflow Biosciences (LON:GENF) (OTCQB:GENFF)

Genflow Biosciences (LON:GENF) (OTCQB:GENFF)

1,455 followers

20h

Genflow Biosciences (LON:GENF) (OTCQB:GENFF) is excited to announce the release of its Annual 2023 Year in Review. This past year, we have achieved significant progress in our primary research areas in Non-Alcoholic Steatohepatitis (NASH) and Werner Syndrome.

Alongside these achievements, we have also made considerable strides in fortifying our corporate structure, enhancing our financial stability, and expanding our market presence to North America.

Read it here: hTtps://loom.ly/EsiO1Rs

#longevity #NASH #Werner #SIRT6 #ageing #Genflow #GENF

Cheers Northeast, all set for a stellar year ahead....in Eric we trust!!! Gl :-)

Hi Harley, could you please try and post the link in segments, spaces between the key words?

Swiss longevity biotech startup Timeline bags €60.6M from L’Oréal, Nestlé, others

January 18, 2024

“Longevity is a new definition of beauty, at the intersection of different scientific disciplines, from decoding biological markers to analysing external exposure. Our investment in Timeline is exciting for its potential to transpose key hallmarks of longevity onto skin health and beauty.”

htTps://siliconcanals.com/crowdfunding/timeline-bags-60-6m/

Genflow in the mix. Gla ;-)

September 2023

Pfizer-backed VitaDAO spins out biotech company

VitaDAO, which funds longevity research, announced the $300,000 financing of a biotechnology company, the DAO's first such investment

hTtps://blockworks.co/news/vitadao-pfizer-biotech-arm

............

Vitadao

VDP-117 Magnaetus Therapeutics

Proposals

Active Proposals

.......................

Reviewer 2

Although no direct relationship or direct mechanistic action with aging, I am enthusiastic about their idea to use parts of the ECM and the protein of interest to target obesity (and metabolic dysregulation), which definitely will have a big impact on the aging society. Also, if they succeed, Novo Nordisk or Eli Lilly is likely to acquire them.

Reviewer 3

After reevaluating the data based on the company’s answers, they do indeed look promising and would allow VitaDAO to enter the weight-loss market. From a commercial perspective, my key concerns are the limited knowledge by the team of what is being developed outside of the two weight-loss drugs that are already commercialized and the lack of a Target Product Profile to be presented to physicians for feedback. I would also recommend as soon as it is feasible to generate head-to-head data vs semaglutide (Novo Nordisk) and tirzepatide (Eli Lilly). Also, given the size of the market, this is not a drug that can be developed and sold on its own, and Business Development activities targeted at Big Pharma must be initiated as soon as possible

hTtps://gov.vitadao.com/t/vdp-117-magnaetus-therapeutics/1417

hTtps://gov.vitadao.com/t/vdp-117-magnaetus-therapeutics/1417

Global online DAO approves launch and financing of MatrixBio to optimal drug candidates for age-related diseases.

VitaDAO, the global online community driving early-stage longevity research through innovative funding collaborations has announced the launch of its very first biotech company – Matrix Biosciences. This significant milestone comes from a community-wide vote and approval in favor of a collaboration with Vera Gorbunova, PhD, Co-Chair of the University of Rochester’s Aging Research Center.

htTps://longevity.technology/news/vitadao-community-launches-its-first-biotech-company/

Another potential imminent non-dilutive award for Genflow, who were awarded a $50k prize in September 2023 along with a new collaboration with Magnaetus Therapeutics from the healthspan challenge and now go forward to the next stage of the challenge, where $1 million will be awarded in January 2024 for the most promising longevity therapies, followed by a grand prize of $5m in June. Gla ;-)

September 2023

Developing therapeutic agents reverse ageing and metabolic decline

Cary Depel; Paul Baldock; Guy Barry |

Magnaetus Therapeutics; Eric Leire, MD | Genflow Biosciences

Competition Sponsor: US National Academy of Medicine

Awardee Year: 2023

Magnaetus Therapeutics believes that in order for longevity measures to be most effective, lifespan increases must be twinned with supportive metabolic interventions. This will ensure the ultimate aim of greater quality, as well as quantity of life, for the increasing majority of our population that is overweight/obese.

To deliver on this aim, Magnaetus is working with Genflow Biosciences to develop peptide therapeutics based upon the multiple metabolic activities of a novel circulating protein. Serum levels of this hormone are increased by exercise and calorie restriction, and suppressed by ageing, obesity and inactivity. It exhibits endocrine effects across numerous aspects of the energy economy, acting to mimic the downstream benefits of exercise and calorie restriction.

Longevity is directly targeted through a feed-forward loop with mTOR suppression. This is coupled with additional capabilities, including appetite suppression, fat burning and insulin production/sensitivity. The discrimination of these activities is realised through selection of individual loops of the parent protein’s repeated helical structure, enabling tailoring of therapeutic response to patient needs through production of specific peptide therapeutics.

htTps://healthylongevitychallenge.org/winners/developing-therapeutic-agents-reverse-ageing-and-metabolic-decline/

hTtps://healthylongevitychallenge.org/event/2023-healthy-longevity-global-innovator-summit/

How the obsession with longevity is shaping the future of skin care

Anti-ageing skin care is on the brink of change. Longevity scientists are raising the bar with an approach that makes skin biologically younger

Can we ‘cure’ ageing? The question came to the forefront in 2023, fuelled by a heady mix of compelling scientific developments and investment from multi-millionaire tech entrepreneurs, against a backdrop of an ageing global population and the recent pandemic.

Together, this has culminated in a borderline obsession with ‘longevity’.

Numerous scientific studies have supported a dramatic increase in longevity in the coming decades, extending the human lifespan to 120 or even beyond.

Breakthroughs such as the successful transfer of a ‘longevity gene’ from naked mole rats to mice, that improved the overall health and lifespan of the mice, are now the stuff of fact, not fiction.

And while ‘longevity’ may have been one of this year’s most popular buzzwords, it has also become a rapidly growing industry, one that is poised to have a profound impact on beauty and wellness in the future.

https://cosmeticsbusiness.com/how-the-obsession-with-longevity-science-is-shaping

Longevity biotech collaborates with Revatis and EXO Biologics on new research into sarcopenia and SIRT6 MRNA delivery.

Longevity biotech Genflow Biosciences has teamed up with Revatis and EXO Biologics on two new longevity research programs, fueled by grants from the Government of Wallonia in Belgium. Genflow is developing gene therapies that target the aging process, with a focus on reducing and delaying age-related diseases.

One of the new research programs, conducted in collaboration with cell therapy company Revatis, is focused on addressing the issue of age-related muscle loss. With funding of €1.34 million, the three-year initiative aims to provide insights into the mechanisms of sarcopenia – the muscle deterioration associated with aging.

Simultaneously, Genflow and exosome-focused biotech EXO Biologics are embarking on a three-year scientific program focusing on mRNA delivery. Supported by a grant of €1.55 million, the initiative will explore an approach using exosomes to encapsulate and transport Genflow’s SIRT6 gene therapy. The ultimate goal is to enable the development of therapeutic interventions for Werner Syndrome, an accelerated aging condition, and other age-related conditions.

Dr Eric Leire, CEO of Genflow said that the new research programs will allow the company to make “meaningful advancements” in the field of longevity.

“Launching both of these programs represents a strategic move to enhance our research capabilities, while contributing to the understanding of age-related conditions,” he said.

Genflow is currently developing a pipeline of SIRT6 gene therapies, with three programs targeting Werner Syndrome, an aggressive form of non-alcoholic fatty liver disease (NASH), and pet longevity. The company’s lead compound is a suspension of an adeno-associated viral vector-based gene therapy based on a variant of the human SIRT6 gene, which is associated with longevity in centenarians.

Disclosure: First Longevity Ltd which operates this website (Longevity.Technology) has a commercial interest in Genflow Biosciences Ltd.

hTtps://longevity.technology/news/genflow-launches-two-grant-funded-longevity-research-programs/

Revatis SA

Innovation in cellular therapy

Revatis is a Spin Off from the University of Liège, dedicated to regenerative medicine and cell therapy. Revatis is based on the scientific discoveries of Prof. D. Serteyn and Dr J. Ceusters and has solid intellectual property and exceptional know-how.

Revatis has a patented technology for obtaining multipotent stem cells from a muscle micro-biopsy. This technology is available for clinical applications in veterinary medicine and for research in human medicine.

In veterinary medicine, Revatis aims to produce autologous stem cells for therapeutic use in horses and companion animals. In human medicine, Revatis is positioning itself as a supplier of personalized stem cells for banking, research, organ-on-a-chip and 3D bioprinting.

htTps://revatis.com/en

.....

Exo Biologics

Unlocking the Potential of Exosomes: The Next Frontier of Nanomedicine

Exosomes are nanometer-sized vesicles containing bioactive molecules secreted by cells. They can be used for the targeted delivery of therapeutic agents.

Exosomes are specific extracellular vesicles that carry RNA, Lipids, and protein messengers, naturally released by various cells. They induce and modulate distinct effects on targeted cells. Depending on their cellular origin, exosomes can also be loaded with specific bioactive molecules, and they have a potency and targeting ability.

EXOB-001, Our Lead Product Candidate

EXOB-001 Investigational Medical Product (IMP) consists of a sterile suspension of allogeneic extracellular vesicles (EVs) derived from cultured human umbilical cord mesenchymal stromal cells (hMSCs).

Human MSCs are characterized by their ability to, among other things, secrete various growth factors and cytokines that modulate the immune system and promote tissue repair and regeneration.

hTtps://www.exobio.be/en/

GenFlow Biosciences

1,413 followers

7h

GenFlow Biosciences (LSE: GENF) (OTCQB: GENFF) is thrilled to announce its partnership with Revatis SA and EXO Biologics in Groundbreaking Aging Research, Fueled by Two Major Research Grants 🧬

"The two research programs are a part of a broader innovation partnership that the Walloon Government has launched, dedicated to Advanced Therapy Medicinal Products (ATMPs). The partnership boasts a substantial budget of 81 million euros, a mix of 60% public funding and 40% private contributions from various companies, spread over three years. This initiative is a collaborative effort involving BioWin, the Health Cluster of Wallonia and the Public Service of Wallonia, representing a significant commitment to advancing medical research and development in the region."

Read more about the exciting new venture here: hTtps://loom.ly/dF-wrxc

#ageing #longevity #healthspan #smallcap